The Ethical Boundaries and Potential of Human Genetic Engineering

In 2018, a Chinese scientist named He Jiankui announced the birth of twin girls whose embryos had been gene-edited using CRISPR technology – ostensibly to protect them from HIV. The announcement sent shockwaves through the global scientific community. He was later convicted by a Chinese court for conducting unauthorized medical procedures, but the episode exposed something far larger than one researcher’s misconduct: it showed that human genetic engineering had moved from a theoretical debate into a practical, urgent, and deeply ethical challenge. The question is no longer just can we alter the human genome – it’s should we, and if so, how far should we go?

What is human genetic engineering? 🔗

Human genetic engineering refers to the deliberate alteration of an individual’s DNA using scientific tools. These changes can range from correcting a single faulty gene responsible for a hereditary disease to theoretically enhancing traits such as intelligence or physical performance. According to the National Human Genome Research Institute (NHGRI), the term “genome editing” is now widely used to describe these techniques – tools that modify the DNA within a cell’s genome with increasing precision. The most prominent of these tools today is CRISPR-Cas9, which has made gene editing faster, cheaper, and more accessible than any method that came before it.

As the Carnegie Endowment for International Peace notes, what once took 13 years and $2.7 billion to accomplish – sequencing the human genome – can now be done in under a day for around $600. This dramatic compression of cost and time has transformed genetic engineering from a laboratory curiosity into a field with real clinical consequences. That power makes clarity on the types, purposes, and limits of genetic engineering more important than ever.

Two major types: somatic vs. germline modification 🔗

The most fundamental distinction in human genetic engineering is between somatic and germline modifications. These two categories differ not just in technique but in their scope of consequences – one affects only the individual being treated, while the other can alter the trajectory of an entire family line.

Somatic gene modification 🔗

Somatic cells are all the non-reproductive cells of the body – blood cells, skin cells, muscle cells, and so on. Modifying them does not affect the reproductive cells (eggs or sperm), which means any genetic changes made through somatic therapy are not passed on to future generations. This makes somatic modification the least ethically controversial form of genetic engineering.

Harvard Law’s I. Glenn Cohen explains that somatic gene therapies involve modifying a patient’s DNA to treat or cure a disease caused by a genetic mutation. In one notable clinical trial, scientists extract blood stem cells from a patient, use CRISPR to correct the mutation causing defective blood cell production, and then reinfuse those corrected cells back into the patient – where they produce healthy hemoglobin. The patient’s sperm or eggs remain unaltered.

According to research published in PMC, somatic therapies are the least controversial gene therapies and are already well-regulated, with more than 2,000 clinical trials completed or underway. The approval of Casgevy – the first CRISPR-based therapy for sickle cell disease – is a landmark example of somatic genetic engineering moving from theory to medicine.

Germline gene modification 🔗

Germline modification is an entirely different matter. The American Society of Gene and Cell Therapy (ASGCT) defines germline gene editing as altering the specific genes of an egg, sperm cell, or early embryo – up to five days after fertilization. Because these are reproductive cells, any edit made will be present in every cell of the resulting person and, crucially, in that person’s own reproductive cells. The changes propagate through future generations.

MedlinePlus, a resource of the U.S. National Library of Medicine, highlights the central ethical tension: people who would be affected by germline modifications are not yet born, and therefore cannot consent to the treatment. This concern – the impossibility of obtaining consent from future generations – is one of the most persistent objections in bioethics.

Clinical use of germline gene editing is currently prohibited in the United States, Europe, the United Kingdom, China, and many other countries. As of 2014, roughly 40 countries had discouraged or banned germline editing research, including 15 nations in Western Europe, citing both ethical and safety concerns.

Negative vs. positive genetic engineering 🔗

Beyond the somatic/germline divide, human genetic engineering is also classified by its purpose. This brings us to the distinction between negative and positive genetic engineering – a conceptual divide that maps closely onto age-old debates about eugenics and human enhancement.

Negative genetic engineering 🔗

Negative genetic engineering uses strategies aimed at preventing the inheritance or expression of harmful genes. The goal is therapeutic: eliminating or correcting genetic mutations that cause disease. Treating sickle cell anemia, cystic fibrosis, or Huntington’s disease through gene therapy falls into this category. The moral justification is relatively straightforward – reducing human suffering by targeting known disease-causing variants.

This category also includes preimplantation genetic diagnosis (PGD) – screening embryos created through IVF to identify those without a genetic disease, and implanting only healthy embryos. The NHGRI notes that some researchers believe there may never be a case where germline embryo editing offers advantages over PGD and IVF, though others acknowledge that germline editing can address genetic needs that PGD cannot.

Positive genetic engineering 🔗

Positive genetic engineering goes a step further: it aims to introduce or enhance traits considered desirable, beyond what is medically necessary. Positive eugenics uses strategies to promote the transmission of traits deemed desirable – whether that’s disease resistance, heightened intelligence, or physical capability. This is where most of the ethical debate intensifies.

Bioethicist W. French Anderson made an influential distinction in 1985 between germline “therapy” for treating genetic disease, enhancement of simple characteristics like height, and eugenics aimed at improving complex human traits. Anderson considered germline therapy ethically acceptable, but drew a firm line against enhancement and eugenics. This framework was widely adopted in subsequent bioethics literature.

The problem, as a study in Nature’s Humanities and Social Sciences Communications points out, is that the line between therapy and enhancement is far from clear in practice. Is correcting a gene variant that predisposes someone to depression “treatment” or “enhancement”? Robert Truog, Director of the Harvard Center for Bioethics, frames it candidly: there are stark distinctions between editing an embryo to prevent sickle cell anemia and editing genes to alter the appearance or intelligence of future generations – and there is a whole spectrum of ethical considerations to navigate in between.

The potential benefits of genetic engineering 🔗

The case for human genetic engineering, particularly in its therapeutic form, is genuinely compelling. The Innovative Genomics Institute at UC Berkeley notes that CRISPR has already demonstrated the potential to treat or even cure genetic diseases. Beyond single-gene disorders, researchers are working on applications for complex conditions including cancer, diabetes, and HIV.

Research in public health contexts points to CRISPR’s potential for strengthening virus surveillance and addressing genetic contributors to chronic diseases. The technology may allow clinicians to correct key asthma-linked genetic variants that increase disease risk in communities heavily exposed to air pollution – conditions that disproportionately affect low-income and minority populations. In this sense, genetic engineering, used responsibly, could become a tool for reducing health disparities rather than deepening them.

Stanford bioengineer Stanley Qi is optimistic that gene therapy will become a pillar of modern medicine in the coming decades, with applications potentially extending to vaccines, regenerative medicine, and even sustainable energy through engineered microbes.

The risks and ethical concerns 🔗

The risks, however, are substantial – and not purely technical. They are deeply philosophical.

Technical risks: off-target effects and mosaicism 🔗

The NHGRI identifies two primary technical dangers: off-target effects – where an edit occurs in the wrong location in the genome – and mosaicism – where only some cells carry the intended edit while others do not. These unpredictable outcomes are particularly alarming in germline editing, where errors would be permanent and heritable. Harvard researchers note that off-target edits could fix one problem while creating another entirely.

The consent problem 🔗

One of the most philosophically significant objections to germline engineering concerns consent. As bioethicists have noted since the late 20th century, future generations cannot give consent to interventions made on their behalf before birth. This creates a profound ethical asymmetry: the people most affected by germline edits are the ones with no voice in the decision.

Justice and access 🔗

The NHGRI raises a pointed concern about genetic inequality: taken to its extreme, germline editing could create distinct social classes defined by the quality of their engineered genome. Research on CRISPR bioethics notes that while families in wealthy countries might afford the cost of germline genome editing, those in developing countries cannot – meaning children in richer nations could gain unfair advantages in intelligence or physical capability over those born elsewhere. This is not a distant hypothetical; it is a structural concern embedded in any market-driven medical technology.

The slippery slope toward eugenics 🔗

A PNAS analysis of the history of the somatic/germline debate shows that early critics worried about exactly this: that framing any genetic intervention as “therapy” could gradually normalize what is effectively the engineering of the human species. The debate between W. French Anderson and theologian Paul Ramsey in 1971 captures the tension cleanly – Anderson saw genetic modification as therapy; Ramsey saw it as an attempt to “eugenically design humanity.” That line has never been fully settled.

The AMA Journal of Ethics underlines that ethics and governance debates must go beyond clinical innovation to include respect for human rights and dignity, and to carefully account for unknown consequences – not just for individuals, but for gene-edited people’s descendants across generations.

Where does the global consensus stand? 🔗

The World Health Organization (WHO) is developing global standards for governance and oversight of germline gene editing. An international commission jointly convened by the U.S. National Academy of Medicine, the U.S. National Academy of Sciences, and the UK’s Royal Society is developing a framework for whether germline editing could ever be ethically conducted, and under what conditions.

A comprehensive scoping review in PMC of global perspectives shows that ethical responses to genetic engineering are shaped not just by science, but by culture and religion. Islamic scholarship permits genetic editing for medical purposes when safety is established and a multidisciplinary team including Sharia specialists is involved. Jewish perspectives tend to frame medically motivated genetic editing as a collaboration between humans and God to save lives. Indigenous communities like the Māori of New Zealand have expressed opposition on grounds that genetic modification disrupts “mauri” – the life essence – and upsets the natural balance.

There is broad consensus that somatic gene therapy for serious disease is ethically permissible and should continue. The debate is sharpest around germline modification – particularly for enhancement rather than treatment. Most bioethicists and researchers agree that germline editing for reproductive purposes should not be clinically attempted at this time, and that ongoing public deliberation is essential before any society moves forward.

The philosophical stakes 🔗

Human genetic engineering ultimately forces us to confront ancient philosophical questions with new urgency. What does it mean to be human? Do we have the right to redesign future persons? Who owns the responsibility for choices made on behalf of generations not yet born? These are not questions that science alone can answer. As bioethicists studying genetic enhancement argue, the very concept of human identity is now being challenged – and with it, questions about whether that identity is immutable, whether it should be modified, and what the psychological and social consequences of such modifications might be for individuals and populations.

The technology, as the Innovative Genomics Institute notes, is advancing far faster than the ethical and regulatory frameworks meant to govern it. That gap is not merely a policy problem – it is a philosophical one. How we fill it will shape what kind of species we choose to be.

What do you think? If negative genetic engineering – editing out hereditary disease – is widely accepted as ethical, where exactly should the boundary be drawn before it shades into positive enhancement? And who should have the authority to draw that line: scientists, governments, religious institutions, or the public at large?

References

1. https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns
2. https://carnegieendowment.org/research/2024/10/mitigating-risks-from-gene-editing-and-synthetic-biology-global-governance-priorities
3. https://patienteducation.asgct.org/understanding-cell-gene-therapy/ethical-issues-germline-gene-editing
4. https://news.harvard.edu/gazette/story/2019/01/perspectives-on-gene-editing/
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC10323846/
6. https://medlineplus.gov/genetics/understanding/therapy/ethics/
7. https://religion.llu.edu/bioethics/adventist-guidelines-genetic-engineering
8. https://www.tandfonline.com/doi/full/10.1080/14699915.2021.1932451
9. https://www.nature.com/articles/s41599-022-01147-y
10. https://innovativegenomics.org/crisprpedia/crispr-ethics/
11. https://news.stanford.edu/stories/2024/06/stanford-explainer-crispr-gene-editing-and-beyond
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC7129066/
13. https://www.pnas.org/doi/10.1073/pnas.2004837117
14. https://journalofethics.ama-assn.org/article/ethics-values-and-responsibility-human-genome-editing/2019-12
15. https://pmc.ncbi.nlm.nih.gov/articles/PMC9793437/
16. https://pmc.ncbi.nlm.nih.gov/articles/PMC6733984/